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Abstract: Intestinal organoids have emerged as the new paradigm for modelling the healthy and
diseased intestine with patient-relevant properties. In this study, we show directed differentiation of
induced pluripotent stem cells towards intestinal-like phenotype within a microfluidic device. iPSCs
are cultured against a gel in microfluidic chips of the OrganoPlate, in which they undergo stepwise
differentiation. Cells form a tubular structure, lose their stem cell markers and start expressing mature
intestinal markers, including markers for Paneth cells, enterocytes and neuroendocrine cells. Tubes
develop barrier properties as confirmed by transepithelial electrical resistance (TEER). Lastly, we show
that tubules respond to pro-inflammatory cytokine triggers. The whole procedure for differentiation
lasts 14 days, making it an efficient process to make patient-specific organoid tubules. We anticipate
the usage of the platform for disease modelling and drug candidate screening.
Keywords: iPSC; intestinal organoids; directed differentiation; gut-on-a-chip; organ-on-a-chip;
microfluidics; 3D cell culture; intestinal inflammation
1. Introduction
In-vitro models that closely mimic the human intestinal epithelium and its physiology are important
tools for drugdevelopment processes [1–3]. As oral drugdelivery is the preferred route of administration [4],
such models have enormous potential to improve and speed up studies of absorption [5], disease
modelling [6], drug metabolism and interactions as well as associated toxicity [7,8]. Therefore, patient-
specific absorption models that take the gut complexity, passive and active transport and patient variability
into consideration could be highly valuable in the evaluation of candidate drugs [9]. In addition to this,
there is a strong need for patient-specific relevant models to mimic intestinal diseases such as inflammatory
bowel disease and irritable bowel syndrome.
One potential cell source for building such models are intestinal organoids derived from induced
pluripotent stem cells (iPSC) [10]. As opposed to human embryonic and adult stem cells, these cells are
not associated with ethical concerns, they are easier to acquire and their generation does not involve the
use of embryonic material [11]. Moreover, the ability of induced pluripotent stem cells to differentiate
into the major cell types of the intestinal epithelium [5,12,13] makes them a useful tool to investigate
the intestinal epithelium’s role in health and disease in-vitro. However, one of the major limitations of
the organoid culture is the overall closed conformation, which makes the apical-luminal surface of
the epithelium inaccessible [12,14] and, therefore, limits the applicability of these cultures for drug
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transport and absorption studies. Additionally, organoids are usually difficult and costly to produce,
requiring one to two months to generate from the iPSC [15,16].
Several protocols exist for the directed in-vitro differentiation of iPSCs into intestinal tissue [12,17].
They usually follow a step wise addition of growth factors or small molecules to mimic intestinal
morphogenesis and cytodifferentiation. In the first step definitive endoderm (DE) is usually acquired
by applying an activin or Wnt-based protocol [18,19]. In the second step the culture is directed towards
hindgut specification through FGF/Wnt induced posterior endoderm patterning [20–22]. In the last
step, an intestinal like phenotype is generated by applying a cocktail of niche factors, including
R-spondin, EGF, and the BMP inhibitor noggin [12,17,23]. These protocols generate human intestinal
organoids (HIOs) containing both epithelial and mesenchymal cells. [17,24] Incorporation of these
cells into microfluidics organ on a chip platforms (OOC) has the unparalleled potential of accelerating
the development of medicines [25,26]. OOC techniques aid physiological relevance of cell cultures
by adding perfusion flow, gradients, mechanical strain and controlled cell–cell interaction in a 3D
environment [27–29]. Moreover, microfluidic approaches allow for both apical and basal access to the
organoids. This feature is critical for many applications and the absence thereof is withholding routine
adoption of current organoid techniques. However, incorporation of HIOs into microfluidic platforms
usually requires an additional FACS-sorting step selecting the epithelial cell population based on the
epithelial adhesion molecule (EpCAM) [17,24]. This additional step further increases the cost and time
needed for incorporation of these cells in large-scale screening applications
In this study we report a protocol for directed differentiation of iPSC into 3D gut-like tubules
directly in microfluidic devices. We make use of the OrganoPlate platform, which is a microtiter
plate-based system, comprising 40 microfluidic chips. Chips comprise a freestanding extracellular
matrix against which the tubule is grown, thus allowing for the interrogation of the epithelial barrier
without interference of artificial membranes. We show that the cells follow a step wise differentiation
through definitive endoderm, hindgut and the intestinal stage. They develop barrier function and
apical to basal polarity over the course of two weeks. Additionally, tubules lose the stem cell markers
and start expressing adult intestinal markers like efflux transporters P-glycoprotein (P-gp/MDR1)
and drug-metabolizing enzymes cytochrome P450 3A4 (CYP3A4). We expose them to inflammatory
cytokines in order to investigate the influence on barrier function and excretion of inflammatory
cytokines. It is the first time that we show establishment of iPSC-derived tubules in microfluidic
devices without the need for an intermediary organoid step. This method enables the quick and
resource-efficient establishment of intestinal models from patient-specific cells that will prove crucial
for routine adoption of microfluidic grown intestinal tubules for drug research and personalised
medicine approaches.
2. Results
2.1. Directed on Organoplate Differentiation of iPSC Towards Gut-on-a-Chip
In this study, we made use of the 3-lane OrganoPlate platform which contains 40 independent
microfluidic chips (Figure 1A) that have 3 microfluidic channels, each with dedicated inlets and outlets
that join in the center of the chip. An observation window in the center of each chip allows microscopic
observation of the intestinal culture (Figure 1B). An extracellular matrix (ECM) gel precursor is
introduced into the middle channel where it is patterned by means of a surface tension technique
called phaseguiding [30]. This yields a free-standing liquid–air meniscus in space of the gel precursor
that is then allowed to solidify. Subsequently, iPSCs are seeded against the ECM gel in the top channel
(Figure 1C). The experimental scheme is shown in (Figure 1D). Cells were directly seeded as stem
cells in OrganoPlate, and after 2 days differentiation was started following the sequence of 2 days
in Definitive endoderm (DE) media, 3 days of Hindgut (HG) media, and 7 to 24 days in the Mature
Intestine (MI) media.
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Figure 1. Seeding and differentiation of hiPSC in the 3-lane OrganoPlate. (A) Artist’s impression of the
bottom-side of the 3-lane OrganoPlate containing 40 individual microfluidic chips. The inlay shows
an individual chip that is communicating with nine connecting wells. (B) Scheme of a single chip
containing three microfluidic channels all having top, middle and bottom inlets (A1, B1 and C1), outlets
(A3, B3 and C3) and an observation window (B2). (C) A schematic representation of hiPSC introduction
to a microfluidic chip in a top (xz plane) and cross sectional view (yz plane); single iPSCs (in red) are
seeded in the top channel and are allowed to adhere for up to 24 h after which media is added and
perfusion initiated, cells start to form tubules by first growing against the ECM gel (blue) and then
covering the whole channel. (D) Schematic of workflow for directed on plate differentiation of iPSC
towards gut tubules.
To optimize the attachment of iPSCs in the OrganoPlate, several conditions were tested including
ECM composition (Collagen I and Matrigel) and coating strategies with recombinant human Vitronectin
(rhVTN), Laminin and no coating at all (Figure S1). The stem cells attached to all coatings but detached
from Laminin on day 4 and did not attach properly in the chips without coating. Moreover, conditions
containingMatrigel as ECMand coatedwith Laminin or VTNweremore likely to be subject to remodeling
of the ECM by the cells, whereas chips having Collagen I and rhVTN as a coating remained more stable.
Once we established and optimized the seeding strategy, we applied a 3-step directed differentiation
protocol adapted for differentiation in microfluidic devices (Figure 1D). In the first step, the definitive
endoderm (DE) differentiation is achieved by treating the iPSC for 24h with Wnt-agonist CHIR99021,
followed by a medium only treatment. Moreover, to assess the differentiation potential of iPSC towards
DE, we performed a small endodermal screen as described by Siler et al. (Figure S2A). iPSC were
treated with either 3 or 4µM CHIR99021 in RPMI/B27 +/− insulin in RPMI-1640 Medium on day 2
and RPMI/B27 +/− insulin in RPMI-1640 on day 3. We did not observe any morphological differences
between the treatments since cells were able to form tubules in all conditions (Figure 2A). There were
no significant changes in DE and HG marker expression as tested by RT-qPCR. TEER measurements
revealed minimal, but not significant barrier function in the 3µMCHIR99021 in RPMI/B27 + insulin in
RPMI-1640 medium condition. The uniform expression of FOXA2 and SOX17 endodermal markers on
day 4 confirms successful differentiation towards the definitive endoderm (Figure 2B).
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Figure 2. Characterization of hiPSC-derived human intestinal-like tubules. (A) 3D reconstruction
image of an iPSC-derived tubule at Day 4 stained with antibodies for SOX17 (green), FOXA2 (red) or
DAPI for DNA (blue). Cells attach and form tubule at the DE stage. (B) Representative images of iPSC
tubules stained for Definitive endoderm markers SOX17 and FOXA2 at day 4. (C) Hindgut marker
CDX2 at day 7. (D) Gene expression was measured using TaqMan qRT-PCR from hiPSC tubules at
different differentiation stages. The following genes were analysed: POU class 5 homeobox 1 (POU5F1,
indicating pluripotency); Nanog homeobox (NANOG, indicating Primitive Streak):, forkhead box a2
(FOXA2, Definitive Endoderm), SRY (sex determining region Y)-box 17 (SOX17, Definitive Endoderm),
and Homeobox protein CDX-2 (Posterior gut). (E) Representative images of iPSC tubules stained for
intestinal markers Lysozyme (LYZ), Villin (VIL) and Chromogranin A (CHGA) at day 28 (green). Nuclei
were stained with DAPI (blue) to visualize the overall morphology. Scale bars = 100 µm. (F) Relative
gene expression analysis of Intestinal markers: Leucine-rich repeat-containing G-protein coupled
receptor 5 (LGR5), Mucin-2 (MUC2), Lysozyme (LYZ), Villin-1 (VIL1), Chromagranin A (CHGA) and
sucrase-isomaltase (SI). (G) Relative mRNA expression of MDR1 (P-gp) and CYP3A4 in iPSC-derived
intestine-like tubules on day 14, day 28 and day 31, human adult colon organoids and Caco-2 cells.
Expression levels were normalized to beta-actin (ACTB), data represented as mean ± SD relative to
the expression in undifferentiated miFF1 hiPSC (n = 2, n ≥ 2–3). The Y-axis represents the LOG10
relative quantification (RQ). Caco-2 cells and primary colon organoid were also included to compare
gene expression and to follow the differentiation of our model during the different stages. Data are
presented as the average of two independent experiments +/− SD (n = 3).
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Activation and inhibition of several signaling pathways like Notch, Wnt, phospoinositide-3-kinase
and BMP are important for the intestinal differentiation [31]. Therefore, in the second step we examined
whether DE cells can be differentiated towards the hindgut (HG) stage within the microfluidic platform.
Cells were exposed to CHIR 99020, BMP-antagonist Noggin (NOG) and Fibroblast growth factor
4 (FGF4) for 3 days. Figure 2A shows a 3D representation of a tubule at day 4. Figure 2A,B show
expression of markers SOX17 and FOXA2 that are representative of the definitive endoderm stage.
In standard culture, the iPSC-derived intestinal organoids form and detach from the cell culture
surface at this stage [12]. Here we confirm that cells form and maintain a tubular shape. On day 7
post-seeding, cells started expressing the intestinal progenitor cell marker caudal type homeobox 2
(CDX2) transcription factor, which is an important factor for intestinal development [32,33] (Figure 2C).
Moreover, cells showed downregulated expression of the pancreatic progenitor cell marker pancreatic
and duodenal homeobox 1 (PDX1), confirming that the cells were of a posterior nature (Figure S2).
This result suggests that iPS cells were successfully differentiated towards intestinal lineage.
In the last step of the differentiation protocol a mature intestinal media (MI) was added to direct
the CDX2+ cells towards more mature intestinal cells. The medium was enriched with epidermal
growth factor (EGF), Wnt agonist R-spondin1 (Rspo1) and Noggin (NOG) emanating the signalling
molecules from supporting mesenchyme for stem cell homeostasis [34]. On day 14 (a week after
starting with MI media), expression of mature intestinal markers was detected by qPCR and the
expression was pronounced at day 28. Stem cell marker Leucine-rich repeat-containing G-protein
coupled receptor 5 (LGR5), goblet cell marker Mucin-2 (MUC2) and brush border sucrase-isomaltase
(SI) were readily detected and on levels similar to human adult colon organoids and Caco-2 (Figure 2F).
Additionally, we detected expression of the Paneth cell marker Lysozyme (LYZ), the enterocyte cell
marker Villin-1 (VIL1) and the neuroendocrine cell marker Chromogranin A (CHGA) which were
distributed throughout the tubule (Figure 2E).
Next, we tested the potential suitability of ourmodel for drug studies. Therefore, we first examined
the gene expression levels of the drug metabolizing enzymes cytochrome P450 3A4 (CYP3A4) and
multidrug resistance protein 1 (MDR1) by real-time RT-PCR analysis. These molecules are important in
drug development, because they are involved in reducing the drug absorption and limiting the systemic
bioavailability [35–38]. The gene expression levels of both CYP3A4 and MDR1 in the hiPSC-derived
tubules were lower than those in adult human colon organoids. However, when compared to cells
with low expression like Caco-2 cells [39] the hiPSC-derived tubules had 4 times higher expression
levels of CYP3A4 (Figure 2G).
One of the major obstacles during the development of this model was the invasion of cells into
the Collagen I ECM which usually happened at the second step or the HG stage, approximately 9 days
post-seeding in the chip. While invasion and remodelling of the ECM are normal processes in the
epitheliumof thegut, it affectedbarrier function as becameapparent in theTEERmeasurements. Initially,
we attempted to apply cost-effective solutions where we increased the concentration of ECM in order
to strengthen the gel and reduce the movement of the gel; however, with limited success. Therefore, we
looked into preventing ECM breakdown by inhibition of matrix metalloproteinases (MMPs). We tested
both a MMP-8 specific inhibitor (CAS 236403-25-1) and a broad spectrum MMP-inhibitor Marimastat
(CAS 154039-60-8) at a 10-µM concentration [40] added from day 4 onwards. The addition of MMP-8
inhibitor prevented the invasion of cells into the ECM and helped in maintaining tubule integrity
(Figure S3A) while it did not affect the expression of mature intestinal markers (Figure S3B). Broad
spectrum MMP-inhibitor (Marimastat), even though effectively preventing ECM invasion, did affect
cell morphology (Figure S3A).
2.2. iPSC-derived Gut-Like Tubules Develop Barrier Properties
To determine whether the hiPSC-derived tubules could be applicable to drug permeability
studies, we evaluated barrier function of the tubules by performing a real-time permeability assay
and transepithelial electrical resistance (TEER) measurements as previously described by Trietsch et al.
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and Beaurivage et al. [6,41]. Figure 3A shows the barrier function of iPSC-derived intestinal tubules.
In short, tubules were perfused with a fluorescently labeled dextran (Figure 3A in blue). In the case of a
tubule, the dye was contained to the lumen, whereas for the ‘no cell control’, fluorescence was observed
all through the microfluidic structure, including adjacent gel layer and secondary perfusion channel.
This demonstrates that tubules form leak-tight barrier. To further assess barrier function, we calculated the
apparent permeability of the tubes over time (see Figure 2B). As shown, tubules became more leak-tight
over time and appeared to be most leak-tight on day 14, with a P-app score of 4.03 × 10−6 cm/s for
150 kDa Dextran and 7.12 × 10−6 cm/s for 4.4 kDa. The TEER value is representative for the integrity of
tight junction dynamics in cell culture models of endothelial and epithelial monolayers. Tubules were
subjected to TEER measurement after confluency was reached on day 4 and up till day 14 (Figure 3C).
TEER values reached a plateau of 30.91 ± 13.37 Ω cm2 on day 14 and maintained this plateau at least
until day 21 (data not shown). Interestingly, approximately 90% of tubules developed a barrier starting
from day 7 (Figure 3D) and after 2 weeks of differentiation these iPSC-derived gut-like tubules exhibited
TEER values similar to primary intestinal tissue with values between 40–100 Ω cm2 [42].
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Figure 3. Barrier function of iPSC-derived intestinal-like tubules. (A) Merge of fluorescent and phase
contrast images of four microfluidic chips perfused in the top channel with fluorescent molecules
(in blue) using 4.4 kDa TRITC-Dextran for 15 min on day 25 of culture. The ‘no cell control’ shows the
passage of the fluorescent dye into the adjacent gel and secondary perfusion channel, whereas in the
chips with iPSC tubules the fluorescent dye is retained by the tubule. (B) P-app value calculated based
on a fluorescent permeability assay using both 4.4 kDa TRITC-dextran and 150 kDa FITC-dextran at day
7 and day 14. Data are represented as mean ± SD. Significance was detected by two-way Anova, n ≥ 12.
(C) Transepithelial electrical resistance (TEER) measurements of iPSC-derived intestine-like tubules
between day 4 and day 14 of culture (N = 3, n ≥ 110). (D) Percentage of iPSC-derived intestine-like
tubules between day 4 and day 14 of culture developing TEER values above 15 Ω cm2. Significance was
detected by ordinary one-way Anova with Dunett’s multiple comparison test. Data are represented as
mean ± SD. (n = 3, n ≥ 110), ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
2.3. Modelling Infammation in iPSC-derived Tubules
We assessed applicability of our model for disease modeling of inflammatory responses as occur
in patients with inflammatory bowel disease. We applied an inflammatory trigger composed of
TNF-α, IL-1B and IFN-γ [6,43]. These cytokines are known to be upregulated in several inflammatory
conditions. We focused on specific aspects of intestinal inflammation like expression and secretion
of pro-inflammatory cytokines by activated epithelial cells. CCL20 is a chemo attractant to recruit
circulating Th17 cells to sites of inflammation [44], IL-6 is a cytokine with main function to regulate
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T cell balance [45], and IL-8 is a powerful neutrophil chemoattractant found in inflamed mucosa [46].
Once added to the tubules, the cytokine cocktail upregulated mRNA expression and the maximal
expression was observed after 48 h for CCL20 and IL6, and the highest expression levels for IL-8 were
observed at 24 h (Figure 4A).
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Figure 4. hiPSC-derived gut tubules respond to inflammatory triggers. (A) Gene expression analysis of
hiPSC-derived gut tubules for CCL20, IL-8, and IL-6 upon stimulation with cytokine cocktail of TNF-α,
IL-1B and IFN-γ. Expression levels are measured upon 24 h, 48 h and 72 h of exposure to the cytokine
cocktail. Data are represented as mean ± SD normalized to ACTB expression (n = 2–3). (B) Secretion of
IL-8 and (C) secretion of IL-6 by triggered hiPSC-derived gut tubules (blue) and Caco-2 tubules (gray)
upon stimulation with the cytokine cocktail. Significance was determined with Multiple t-tests (one
per row) and discovery determined using the Two-stage linear step-up procedure of Benjamini, Krieger
and Yekutieli, with Q = 1%. Each row was analyzed individually, without assuming a consistent SD.
Data are represented as mean ± SD. (n ≥ 5) ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
We next investigated the release of IL-6 and IL-8 by iPSC gut tubules compared to Caco-2
tubules, in response to cytokine cocktail exposure, using enzyme-linked immunosorbent assay (ELISA).
IL-8 production after the addition of the inflammatory trigger to the iPSC-derived intestinal tubules
was significantly increased after the first 24 h, and then decreased significantly for each of the following
24 h, decreasing from a mean of 1206 ± 303 pg/mL to 869 ± 336 pg/mL at 48 h and 613 ± 167 pg/mL at
72 h. The IL-8 secretion of Caco-2 tubules showed a reversed tendency, increasing from 607 ± 66 pg/mL
at 24 h, to 734 ± 55 pg/mL at 48 h and 859 ± 109 pg/mL at 72 h (Figure 4B).
After cytokine stimulation, the IL-6 production was high for the iPSC-derived tubules
97.40 ± 86.5 pg/mL, 1072 ± 460 pg/mL and 898 ± 278 pg/mL at 24 h, 48 h and 7 2h, respectively.
Caco-2 tubules had low IL-6 production at all of the time points (Figure 4C). We thus conclude that
iPSC-derived tubules are more responsive to cytokine stimuli than Caco-2 tubules, indicating a more
physiologically relevant behavior.
3. Discussion
In summary, we developed a fully defined and partially small molecule-based differentiation
protocol [10,12,24] to directly differentiate from iPSC towards gut-like tubules in amicrofluidic platform.
Tubules were successfully differentiated to definitive endoderm after 4 days in culture and reached
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expressed hindgut markers at day 7. We showed the upregulation of MDR1 and CYP3A4—enzymes
involved in intestinal drug metabolism. Furthermore, the intestinal tubules were shown to have a
barrier function as assessed by both barrier integrity assay and TEER measurements. We demonstrated
that these tubules respond to inflammatory cytokines. Other than Caco-2 cells, our intestinal tubes
show increased production of IL-6 upon stimulation. We thus anticipate that the model can be used for
ADME tox studies as well as for modelling intestinal inflammation.
The main purpose of this study was to develop a method to generate iPSC-derived gut-like
tubules directly, robustly and reproducibly in a microfluidic platform, while omitting the long and
labor-intensive intermediate step of organoid generation. Thus, we reduce culture and differentiation
times, as well as usage of media and associated growth factors. This is of crucial importance, to consider
microfluidics-based culture for routine use in drug development and basic research alike. An advantage
of using such microfluidic techniques is that we have straightforward access to both the apical as well
as basal side of the epithelium.
For the differentiation of the iPSC cells towards definitive endoderm in the OrganoPlate, we used a
short pulse of smallmoleculeWnt activatorCHIR99021 instead of the recombinantActivinAmolecule [17]
based protocol. GSK-3 inhibition by CHIR99021 alone is sufficient for the generation of SOX17 and
FOXA2 positive cells [19,47]. This step shortens the definitive endoderm phase from 5 days to 2 days.
In the subsequent step FGF4 and CHIR99021 signaling were applied as they are known to induce the
expression of the posterior endoderm marker CDX2 [12,48]. This stage of differentiation can also be
achieved by applying a BIO/DAPT combination of small molecules [49]. However, BIO is known to
have various off target effects including inhibition of the JAK/STAT signals [50], which are necessary
for intestinal proliferation [51]. We further demonstrated that a combination of niche factors including
Noggin, R-spondin and EGF are sufficient to induce the differentiation of the iPSCs towards intestinal
progenitor cells. Recombinant protein (e.g., Wnt3a) nor a small molecule Wnt agonist (e.g., CHIR99021)
are not used in this step. However, since the differentiated epithelium includes Paneth cells, we assume
that the stem cell niche is supported [52]. In future studies, we will further investigate this aspect.
We showed the applicability of our model for permeability studies by performing large scale TEER
measurements (n = 110) over 14 days of culture in the microfluidic device. Thus, demonstrating that
our model can develop a barrier starting from day 4 and reaching levels similar to the primary tissue
in 14 days between 40–100 Ω cm2 [42] with the addition of a MMP-8 inhibitor. In contrast, the average
TEER values for Caco-2 cultures ranges between 500–1500 Ωcm2 [53,54]. For the applicability of the
model in drug discovery studies, it should be noted that the P-gp transporter (MDR1) expression is lower
than for the human colon Organoids and Caco-2 tubules. However, this is consistent with previous
findings [49,55,56] of stem cell differentiated gut-like tissue, and suggests that our hiPSC-derived gut-like
tubules resemble the fetal tissue rather than the adult one.
Lastly, we were able to demonstrate that our system is susceptible to stimulation with inflammatory
cytokines, demonstrating the potential for modeling an inflammatory condition such as is present in
patients with inflammatory bowel disease. The iPSC-derived intestinal-like tubules showed a significant
increase in IL-6 and IL-8 release after 48 and 24 h, respectively. While Caco-2 cells are capable of producing
IL-8 after several days of culture [57], in the literature there is conflicting evidence regarding IL-6 secretion
by Caco-2 [17,58]. In our experiments, we were not able to detect it. The function of interleukin-6 in the
intestinal epithelium is to increase proliferation and survival by an autocrine signaling mechanism [59].
Cells that express IL-6 receptors are crypt Paneth cells [43,60]. Caco-2 cells, when differentiated, are
known to resemble enterocytes of the small intestine and, therefore, it is explainable that they are unable
to produce IL-6 in large quantities [61].
In conclusion, in this proof-of-principle study, we demonstrated the possibility for iPSCs to be
successfully directed towards gut-like phenotype in a robust, reproducible and cost-effective manner, all in
a 3D microfluidic device and within 14 days post-seeding. Moreover, the iPSC develops into relevant
leak-tight tubules with the expression of intestinal markers, similar to existing models, and with significant
response to inflammatory triggers. This allows for the efficient establishment of patient-specific in-vitro
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models, which have the potential to be used for drug discovery and for studying inflammatory processes
in the intestine.
4. Materials and Methods
4.1. Ethics Statement
The research described here has been performed according to applicable Dutch and UK national
ethics regulations and was conducted within MIMETAS BV (Leiden, The Netherlands) and the
University of Sheffield (Sheffield, United Kingdom). Colon organoid line was previously derived at
the Hubrecht institute, Utrecht, the Netherlands from colonic tissue obtained from The Diakonessen
Hospital Utrecht with informed consent and the study was approved by the ethical committee [62].
4.2. Cells
Human induced pluripotent stem cells (hiPSC; miFF1 UOSi001-A) [63] were obtained from the
University of Sheffield (Sheffield, United Kingdom), cultured in a standard gas atmosphere with 95%
humidity and 5% CO2 at 37 ◦C in feeder-free conditions using 0.5 mg/mL Vitronectin Recombinant
Human Protein (Thermo Fisher Scientific No. A14700)-coated 6 well plates. Routine passaging of
cells was performed with 0.5 mM EDTA (Thermo Fisher Scientific, 15-575-020). Essential 8 medium
(Thermo Fisher Scientific No. A1517001) supplemented with 10 µM Y-27623 ROCK inhibitor (Merck
No. 688000-1MG) was used in the first 24 h post-passaging. Essential 8 medium (Thermo Fisher
Scientific No. A1517001) was used for the expansion after the initial 24 h.
Human colon adenocarcinoma cell line Caco-2 (ECACC 86010202) was cultured as described
earlier [6,41]. In short, Caco-2 cells were cultured at 5% CO2 at 37 ◦C in an EMEM (ATCC, Manassas,
VA, USA) supplemented with 10% FBS (Gibco, Waltham, MA, USA), 1% NEAA (Gibco, Waltham,
MA, USA) and 1% penicillin/streptomycin (Gibco, Waltham, MA, USA). Cells were passaged before
reaching 80% confluency and used between passage 47–60.
Human Colon Organoids were obtained from the Hubrecht Institute (Utrecht, Netherlands)
and cultured as described previously [62]. In short, organoids were embedded in Matrigel
GFR (Corning, 356231) and cultured in 24-well plates in 1× CNM media containing 50% Wnt3a
CM, Advanced Dulbecco’s modified Eagle medium/F12 (ThermoFisher 12634028) supplemented
with penicillin/streptomycin, 10 mmol/L HEPES, 1× Glutamax, 1× B27 supplement, 1.25 mM
N-acetyl-cysteine (Sigma A9165), 10 mM Nicotinamide (Sigma, N0636), 5 nM Gastrin (Sigma, G9145),
100 ng/mLNoggin (Peprotech 120-10C), 250 ng/mLRspondin-3 (Tocris, 3500), 50 ng/mLEGF (Peprotech,
AF-100-15), 500 nM A83.01 (Tocris 2939), 10 µM SB2020190 (Sigma, S7076) and 50 µg/mL Primocin
(Invivogen ANT-PM-2). Culture was passaged every 7 days and Y-27632 dihydrochloride (Torcis 1254)
was added to the media for the initial 48 h.
Cell were routinely tested against mycoplasma contamination and were found negative.
4.3. OrganoPlate Seeding and Tubule Formation
ECM loading was prepared as described previously in a 3-lane 400 µmOrganoPlate (Mimetas No.
4003-400-B) [41,64]. In short, 1.5–2 µL of 6.64 mg/mL collagen-I (Corning,354249) was dispensed into the
middle inlet. The OrganoPlate was placed in the incubator for 15 min to allow the polymerization of the
collagen-I gel. After solidification of the gel, 30 µL HBSS was placed in the middle inlet to prevent the
gel from drying out and the plate was placed back into the incubator until use. Then the OrganoPlate
was coated with 0.5 mg/mL Vitronectin Recombinant Human Protein (Thermo Fisher Scientific, A14700)
diluted in ice-cold PBS added in the topmedium inlet for 60 min at room temperature (RT) before seeding.
Cells were dissociated to a single cell suspension and the concentration was adjusted to 5000 cells/µL
in mTeSR medium supplemented with 10 µM Y-27623 ROCK inhibitor. HBSS was removed from the
gel inlets and 2 µL cell suspension was inserted in the top medium outlet. Next, 1 µL of liquid was
removed from the topmedium inlet to assist the seeding of cells in a coated channel. After which, 50 µL of
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mTeSR medium (STEMCELL Technologies,85850) supplemented with 10 µMY-27623 ROCK inhibitor
was added to the top medium inlet to prevent evaporation. The OrganoPlate was placed flat and static in
a humidified chamber to allow the cells attachment for 6 h. Subsequently, 50 µL of mTeSR medium was
added to the top medium inlet, bottom medium inlet and outlet as well. Cells were then incubated in a
humidified chamber on an interval rocking platform switching between a +7◦ and –7◦ inclination every
8 min (OrganoFlow; Mimetas BV), to induce bidirectional flow.
4.4. Directed on Plate Differentiation of iPSC
After the initial 48 h of mTeSR medium in the Organoplate, cells were exposed to definitive
endoderm differentiation medium (DE) Table S1. After additional 48 h the differentiation on the
definitive endoderm was completed, the cultures were started on Hindgut differentiation medium
on day 4 (HG) Table S1. These conditions were maintained for 3 days. Cells were further directed
towards the mature intestine with mature intestine medium (MI) Table S1 for an additional two to
three weeks, with medium changes every 3 to 4 days (Table S1). An amount of 10 µMMMP-8 inhibtor
(Fischer Scientific No. 44-423-7) or 10 µMMarimastat (MERCK,. M2699) was added to the cultures
once the Hindgut stage of differentiation was started to reduce the invasion of cells into the ECM.
4.5. Barrier Intergrity Assay (BI Assay) and Calculation of Aperent Permeability (P-App)
The barrier integrity assay was performed to assess the barrier integrity of a boundary tissue and
has been described in detail previously [6,41,64]. In short, basal media was added to the middle and
bottom inlets and outlets. The top inlets or the lumens of the intestinal tubules were perfused with
media containing high 0.5 mg/mL FITC-dextran (150 kDa, Sigma No. 46946) and low molecular weight
TRITC-dextran (4.4 kDa, Sigma No. T1037). Plates were imaged using ImageXpress XLS Micro HCI
system with an interval of every 3 min for total time of 15 min. The permeability of the fluorescent
particles was quantified by determining the fluorescence levels in the basal gel region and normalizing
it to the fluorescence in the lumen of the tubule to compensate for bleaching effects. The ratio between
the fluorescent signal in the basal and apical region of the tube was analyzed using Fiji. Cell-free chips
were taken as negative controls. These data were then used to calculate the apparent permeability
value (P-app) according to van Duinen et al. [65].
4.6. TEER Measurements
Transepithelial electrical resistance (TEER) was measured at different time points using an
automatedmultichannel impedance spectrometer designed for usewith the OrganoPlate (OrganoTEER,
Mimetas). Before each measurement, medium was added in the middle inlets and outlets and the
OrganoPlate was returned in the incubator (37 ◦C, 5% CO2) to equilibrate for an hour. The electrode
board of the OrganoTEER is matched to the OrganoPlate, such that when an OrganoPlate is placed in
the OrganoTEER, electrode pairs are inserted in the medium in all inlet and outlet wells connecting
to the basal and apical side of all tubes. Point impedance measurements were performed at room
temperature by frequency sweep from 10 Hz to 1 MHz (41 points; precision, 0.2). Data were analyzed
using the OrganoTEER software, which automatically extracts the TEER contribution (in Ohm) from
the measured spectra and normalizes it to Ohm.cm2 by multiplying by the tubule-ECM interface
(estimated at 0.0056 cm2).
4.7. Cytokine Trigger and ELISA for Activation Molecules
iPSC and Caco-2 tubules treated with cytokine-triggering medium consist of IL-1β, IFN-γ and
TNF-α at 50, 50 and 50 ng/mL, respectively (ImmunoTools, Friesoythe, Germany), for 24, 48 and
72 h. Medium was collected from the Top and Bottom inlets and outlets, pooled and stored at −80 ◦C
until further analysis. CXCL6 and CXCL8 secretion were quantified using the Human IL-6 DuoSet
ELISA (RD systems No. DY206) and Human IL-8/CXCL8 DuoSet ELISA (RD systems No. DY208),
respectively, according to the manufacturer’s instructions.
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4.8. Immunocytochemistry (ICC)
Cells were fixated with 3.7% formaldehyde in HBSS at RT for 15 min. Cells were washed twice
with PBS for 5 min and subsequently washed once with 4% Fetal bovine serum (FCS) in PBS for 5 min,
followed by permeabilization with 0.3% Triton X-100 in PBS for 10 min. After which, the cells were
washed with 4% Fetal bovine serum (FCS) in PBS for 5 min and blocked with 2 % FCS, 2% Bovine serum
albumin (BSA), 0.1% Tween-20 in PBS for 30 min. Next, cells were incubated overnight with primary
antibodies diluted in blocking buffer. Cells were washedwith 4% Fetal bovine serum (FCS) in PBS twice
for 3 min and subsequently incubated with secondary antibodies for 30 min, followed by a washing
step and nuclei staining with Hoechst 33342. The antibodies used: SOX17 (R&D Systems, MAB19241
1/100), FOXA2 (R&D Systems AF2400. 1/100) CDX2 (R&D Systems, AF3665, 1/100), Villin (Santa
Cruz, 58897, 1/200), Chromagranin A (Rabbit Santa, cruz13090, 1/200), Lysozyme (Thermo Fischer,
MA1-82873,1/200), Isotype Rabbit (Life Technologies, 86199, 1/250) Isotype Goat (Life Technologies,
026202, 1/250), Isotype Mouse (Invitrogen, 08-6599 1/250), Goat Alexa Fluor 488 (Invitrogen, A11055
1/250) Mouse Alexa Fluor 555(Life Technologies, 1736967, 1/250), Rabbit Alexa Fluor 647 (MERCK,
SAB460177 1/250) and cell stains Actin Green (LifeTechnologies, R37110), Hoechst 33342 (Thermo
Fischer, H3570, 1/1000).
4.9. Gene Expression Anaysis
TotalRNAwas isolatedusingRNeasyMicrokit (QiagenNo. 74004) according to themanufacturer’s
instructions; two to three chipswere pooled into one sample. Wefirst determined theRNAconcentration
with NanoDrop OneC Microvolume UV-Vis Spectrophotometer (Thermo Fischer) and adjusted it to a
min concentration of 30 ng/µL in DEPC-treated milliQ water. M-MLV reverse transcriptase (28025013;
Thermo Scientific) was used to synthesize cDNA by following the manufacturer’s protocol. Finally,
qPCR was performed by using FastStart Essential DNA Green Master (Roche, 06402712001) for SYBR
Green I-based real-time PCR and FastStart Essential DNA Probe Master (Roche, 06402682001) for
TaqMan based real-time PCR.
SYBR Green primers used during experiments. GeneID, NCBI number, Primer sequence 5′–3′:
ACTB NM_001101.3
F: CTCTTCCAGCCTTCCTTCCT R: AGCACTGTGTTGGCGTACAG,
SI NM_001041.3
F: GTAAGGAGAAACCGGGAAGC R: TGTCCATGGTCATGCAAATC,
CYP3A4NM_001202855.3
F: TTTACCCAATAAGGCACCACC R: TTGCAGACCCTCTCAAGTC
CXCL6 NM_002993.4
F: TGTTTACGCGTTACGCTGAG R: AACTTGCTTCCCGTTCTTCA
CXCL8 NM_000584.4
F: CAAGAGCCAGGAAGAAACCA R: ACTCCTTGGCAAAACTGCAC
CCL20 NM_004591.3
F: GCAAGCAACTTTGACTGCTG R: GATGTCACAGCCTTCATTGG
TaqMan probes for: OCT4 Hs04260367_gH FAM 77 NANOG Hs04260366_g1 FAM 99 SOX17
Hs00751752_s1 FAM 149 FOXA2 Hs05036278_s1 FAM 144 CDX2 Hs01078080_m1 FAM 81 PDX1
Hs00236830_m1 FAM 73 LGR5 Hs00969422_m1 FAM 61 LYZ Hs00426232_m1 FAM 67 VIL1
Hs01031722_g1 FAM 72 MUC2 Hs00159374_m1 FAM 81 CHGA Hs00900375_m1 FAM 88 ABCB1
Hs00184491_m1 FAM 110 ACTB Hs01060665_g1 VIC 63 06402712001)
Results were normalized relative to ACTIN expression for both Taqman and SybrGreen experiments.
4.10. Statistics and Data Analysis
Data were analyzed using GraphPad Prism software version 7 (GraphPad Software, La Jolla, CA,
USA). Unless stated otherwise, values are expressed as mean ± Standard Deviation (SD). ANOVA and
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Student’s t-tests were used to determine the statistical significance. Differences with p < 0.05 were
considered significant (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). All graphs
shown contain results from one or two representative experiments containing at least three technical
replicates (chips). Number of replicates used are provided in the figure legends.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/14/4964/s1,
Figure S1: Optimization of ECM and coating strategy for better attachment and tubule maintenance of iPSC;
Figure S2: Endodermal potential screen and barrier integrity of iPSC; Figure S3: Maintenance of tubular shape of
differentiated iPSC derived gut-like tubules within a microfluidic device with matrix metalloproteinases inhibitors;
Table S1: Components of directed differentiation media.
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